REG - Redx Pharma plc - New Grant of Options

Redx PharmaAnnouncement

02/12/2020 07:13

RNS Number : 2030H
  
Redx Pharma plc
  
02 December 2020
  
 

Redx Pharma plc
("Redx" or "the Company")
 
New Grant of Options
 
Alderley Park, 2 December 2020 Redx Pharma (AIM:REDX), the drug discovery and development company focused on cancer and fibrosis, announces new options awarded under the Redx All Employee Share Option Scheme (the "Scheme"), as adopted on 1 July 2020.   
 
The Board has authorised the conditional grant of additional options to Lisa Anson (Chief Executive Officer) and Richard Armer (Chief Scientific Officer) on 2 December 2020, both of whom are classed as PDMRs, as set out further below. The options are being granted at 56p per ordinary share, being the price of the Placing and Open Offer announced earlier today, with the grant becoming unconditional once the Placing Shares and the Open Offer Shares have been admitted to trading on AIM, which is dependent, inter alia, on the passing by Shareholders of certain resolutions at the General Meeting of the Company being convened at 11.00 a.m. on 21 December 2020.
 
Once the option grant becomes unconditional, any subsequent vesting will be subject to certain time and performance criteria having been met.
 
 



Name


Position


Number of Options Conditionally Granted


Vesting Date


Total Options Held Following the Conditional Grant




Lisa Anson (Director/PDMR)


Chief Executive Officer


451,145
451,145
451,144
2,030,152


2 December 2021
2 December 2022
2 December 2023
2 December 2023 (subject to performance conditions)


 
 
 
11,683,586


























Richard Armer
(PDMR)


Chief Scientific Officer


231,250
231,250
231,251
1,040,627


2 December 2021
2 December 2022
2 December 2023
2 December 2023 (subject to performance conditions)


 
 
 
5,984,378



 
In addition, options over a further 1,350,000 Ordinary Shares of 1p each will be granted on 2 December 2020 to certain new staff of the company under the Scheme on an unconditional basis. These options will also be granted at 56p, and are not subject to performance conditions.
 
Following the grants referred to above, and assuming the associated conditions are met in relation to the conditional grant, the Company will have granted options over a total of 28,057,964 Ordinary Shares representing 10.2 per cent. of the share capital in issue following completion of the Placing and the associated  issue of 32,806,159 Ordinary shares to Redmile and Sofinnova in aggregate pursuant to their conversion of £5,084,954.65 of the principal amount of the convertible loan notes issued to them on 4 August 2020 (but ignoring any Ordinary Shares issued in the Open Offer, the take-up of which is currently uncertain).  In addition, certain ex-employees continue to hold options, totalling 2,340,800 shares, representing 0.9 per cent. of the share capital that will be in issue following completion of the Placing and aforementioned conversion (but not the Open Offer). The number of options that may be awarded under the Scheme, and all prior share incentive plans, remains limited such that the aggregate number of Ordinary Shares of 1p each under option will be less than 15 per cent. of the total issued share capital of the Company.
 
 



For further information, please contact:


















Redx Pharma Plc 


T: +44 1625 469 918




Iain Ross, Chairman
Lisa Anson, Chief Executive


















SPARK Advisory Partners (Nominated Adviser)


 T: +44 203 368 3550




Matt Davis/Adam Dawes


















WG Partners LLP (Broker)


T: +44 20 3705 9330




Claes Spång/Chris Lee/David Wilson




























FTI Consulting


T: +44 20 3727 1000




Simon Conway/Ciara Martin








 
 







 
About Redx Pharma Plc 
 
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
 
The Company's  core capability  of converting  medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHXFLLBBLLBFBZ